CVRx, a private medical device company, secured equity financing totaling $93 million and a new $20 million debt facility. CVRx plans to use the proceeds to complete the Baroreflex Activation Therapy for heart failure pivotal clinical trial and to expand its global commercial activities.

CVRx also closed a $20 million term loan agreement with Oxford Finance. A portion of the loan proceeds from this new debt facility was used to repay an existing loan. Armentum Partners served as an advisor to CVRx for this financing.

In addition, the company completed a private equity financing totaling $57.7 million. An additional $35.3 million has already been subscribed by the same investors and will close upon the company’s achievement of a certain operational milestone. Leerink Partners acted as a financial advisor during this equity fund raising process.

Johnson & Johnson Innovation was the lead investor, with participation from existing investors New Enterprise Associates and Ysios BioFund I F.C.R. New investors in this series G financing included Gilde Healthcare Partners, Action Potential Venture Capital and Windham Venture Partners.